Halozyme Therapeutics Inc (HALO)

Current ratio

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total current assets	US$ in thousands	1,085,340	746,424	739,013	926,287	554,764
Total current liabilities	US$ in thousands	139,100	112,494	130,789	117,147	421,385
Current ratio		7.80	6.64	5.65	7.91	1.32

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $1,085,340K ÷ $139,100K
= 7.80

The current ratio of Halozyme Therapeutics Inc has shown a consistent improvement over the past five years. Starting at 1.32 in December 2020, the ratio increased significantly to 7.91 in December 2021, indicating a substantial strengthening of the company's short-term liquidity position.

Although there was a slight decrease in the current ratio in December 2022 (5.65), it remained at a healthy level, suggesting that the company still maintains an adequate level of current assets to cover its short-term liabilities.

In December 2023 and December 2024, the current ratio further improved to 6.64 and 7.80, respectively. These ratios indicate a continuing positive trend in the company's ability to meet its short-term obligations using its current assets.

Overall, the upward trend in the current ratio of Halozyme Therapeutics Inc reflects a positive liquidity position and indicates that the company has improved its ability to cover its short-term liabilities with its current assets over the past five years.